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A B S T R A C T
Background
Transurethral radiofrequency collagen denaturation is a relatively novel, minimally invasive device-based intervention used to treat
individuals with urinary incontinence (UI). No systematic review of the evidence supporting its use has been published to date.
Objectives
To evaluate the efficacy of transurethral radiofrequency collagen denaturation, compared with other interventions, in the treatment of
women with UI.
Review authors sought to compare the following.
• Transurethral radiofrequency collagen denaturation versus no treatment/sham treatment.
• Transurethral radiofrequency collagen denaturation versus conservative physical treatment.
• Transurethral radiofrequency collagen denaturation versus mechanical devices (pessaries for UI).
• Transurethral radiofrequency collagen denaturation versus drug treatment.
• Transurethral radiofrequency collagen denaturation versus injectable treatment for UI.
• Transurethral radiofrequency collagen denaturation versus other surgery for UI.
Search methods
We conducted a systematic search of the Cochrane Incontinence Group Specialised Register (searched 19 December 2014), EMBASE
and EMBASE Classic (January 1947 to 2014 Week 50), Google Scholar and three trials registries in December 2014, along with
reference checking. We sought to identify unpublished studies by handsearching abstracts of major gynaecology and urology meetings,
and by contacting experts in the field and the device manufacturer.
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Selection criteria
Randomised and quasi-randomised trials of transurethral radiofrequency collagen denaturation versus no treatment/sham treatment,
conservative physical treatment, mechanical devices, drug treatment, injectable treatment for UI or other surgery for UI in women
were eligible.
Data collection and analysis
We screened search results and selected eligible studies for inclusion. We assessed risk of bias and analysed dichotomous variables as
risk ratios (RRs) with 95% confidence intervals (CIs) and continuous variables as mean differences (MDs) with 95% CIs. We rated
the quality of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach.
Main results
We included in the analysis one small sham-controlled randomised trial of 173 women performed in the United States. Participants
enrolled in this study had been diagnosed with stress UI and were randomly assigned to transurethral radiofrequency collagen denatu-
ration (treatment) or a sham surgery using a non-functioning catheter (no treatment). Mean age of participants in the 12-month multi-
centre trial was 50 years (range 22 to 76 years).
Of three patient-important primary outcomes selected for this systematic review, the number of women reporting UI symptoms after
intervention was not reported. No serious adverse events were reported for the transurethral radiofrequency collagen denaturation arm
or the sham treatment arm during the 12-month trial. Owing to high risk of bias and imprecision, we downgraded the quality of
evidence for this outcome to low. The effect of transurethral radiofrequency collagen denaturation on the number of women with an
incontinence quality of life (I-QOL) score improvement ≥ 10 points at 12 months was as follows: RR 1.11, 95% CI 0.77 to 1.62;
participants = 142, but the confidence interval was wide. For this outcome, the quality of evidence was also low as the result of high
risk of bias and imprecision.
We found no evidence on the number of women undergoing repeat continence surgery. The risk of other adverse events (pain/dysuria
(RR 5.73, 95% CI 0.75 to 43.70; participants = 173); new detrusor overactivity (RR 1.36, 95% CI 0.63 to 2.93; participants = 173);
and urinary tract infection (RR 0.95, 95% CI 0.24 to 3.86; participants = 173) could not be established reliably as the trial was small.
Evidence was insufficient for assessment of whether use of transurethral radiofrequency collagen denaturation was associated with an
increased rate of urinary retention, haematuria and hesitancy compared with sham treatment in 173 participants. The GRADE quality
of evidence for all other adverse events with available evidence was low as the result of high risk of bias and imprecision.
We found no evidence to inform comparisons of transurethral radiofrequency collagen denaturation with conservative physical treat-
ment, mechanical devices, drug treatment, injectable treatment for UI or other surgery for UI.
Authors’ conclusions
It is not known whether transurethral radiofrequency collagen denaturation, as compared with sham treatment, improves patient-
reported symptoms of UI. Evidence is insufficient to show whether the procedure improves disease-specific quality of life. Evidence is
also insufficient to showwhether the procedure causes serious adverse events or other adverse events in comparison with sham treatment,
and no evidence was found for comparison with any other method of treatment for UI.
P L A I N L A N G U A G E S U M M A R Y
Low-temperature heat via the urethra to treat women with urinary leakage
Review question
We studied the question of whether using low-temperature heat via the urethra is safe and helps women with involuntary urinary
leakage. We looked for randomised studies comparing this treatment with no treatment or with other treatment forms.
Background
Involuntary urinary leakage is a troubling problem that many women face. Many types of treatment are available to help these women,
such as changes in behaviour and different types of surgery. Low-temperature heat via the urethra is a newer form of treatment that can
be used to treat women in the office rather than in the operating room. How well this treatment works and how safe it is are not well
understood.
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Study characteristics
We searched for all randomised controlled trials that studied this form of treatment up to December 2014. We found only one trial of
173 women who were troubled by urinary leakage. On average, these women were 50 years of age. Through random assignment, two-
thirds of them were treated with low-temperature heat via the urethra; the others did not receive this treatment. Researchers followed
these women for 12 months. The makers of this treatment paid for the study.
Key results
No information revealed whether more or fewer women complained of urinary leakage at 12 months, or whether there was a difference
in the number of women having repeat surgery. The study did not show that quality of life was improved. Evidence was insufficient to
show whether there was a difference in serious or minor side effects.
Quality of the evidence
Using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, we found no evidence for the
question of whether low-temperature heat via the urethra changed the number of women who leaked. We found low-quality evidence
related to serious side effects, minor side effects and quality of life when compared with no treatment because data were limited and
the study was poorly conducted. We found no evidence on whether this treatment changed the number of women who underwent
another surgery. Because we did not find studies that compared this treatment with other treatments, we do not know whether this
treatment results in better or worse outcomes.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Transurethral radiofrequency collagen denaturation compared with no treatment/sham treatment for women with UI
Patient or population: women with symptomatic UI
Settings: academic and community practices in the United States
Intervention: transurethral radiofrequency collagen denaturation
Comparison: no treatment/sham treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No treatment/sham
treatment
Transurethral radiofre-
quency collagen denatu-
ration
Participant-reported mea-
sures: number of women
reporting UI symptoms
- - Not estimable 0 (0 studies) - No evidence available
Serious adverse events
Follow-up: 12 months
0 per 1000 0 per 1000
(0 to 0)
Not estimable 173
(1 RCT)
⊕⊕©©
Lowa,b
No serious adverse
events occurred in 1 in-
cluded study
Disease-specific quality
of life: number of women
with an I-QOL score im-
provement≥ 10 points at
12 months
434 per 1000 482 per 1000
(334 to 703)
RR 1.11 (0.77 to 1.62) 142
(1 RCT)
⊕⊕©©
Lowa,c
Repeat con-
tinence surgery: number
of women undergoing re-
peat continence surgery
- - Not estimable 0 (0 studies) - No evidence available
4
T
ra
n
su
re
th
ra
l
ra
d
io
fre
q
u
e
n
c
y
c
o
lla
g
e
n
d
e
n
a
tu
ra
tio
n
fo
r
th
e
tre
a
tm
e
n
t
o
f
w
o
m
e
n
w
ith
u
rin
a
r
y
in
c
o
n
tin
e
n
c
e
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Other adverse event: pain/
dysuria:
dysuria
Follow-up: 12 months
16 per 1000 91 per 1000
(12 to 694)
RR 5.73
(0.75 to 43.70)
173
(1 RCT)
⊕⊕©©
Lowa,d
Other adverse event:
(new) detrusor overac-
tivity: overactive bladder
symptoms
Follow-up: 12 months
127 per 1000 173 per 1000
(80 to 372)
RR 1.36
(0.63 to 2.93)
173
(1 RCT)
⊕⊕©©
Lowa,d
Other adverse event: uri-
nary tract infection
Follow-up: 12 months
48 per 1000 45 per 1000
(11 to 184)
RR 0.95
(0.24 to 3.86)
173
(1 RCT)
⊕⊕©©
Lowa,d
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; MD: Mean difference; I-QOL: Incontinence Quality of Life; RCT: Randomised controlled trial; RR: Risk ratio; UI: Urinary incontinence.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aDowngraded for study limitations (-1): high risk of bias.
bDowngraded for imprecision (-1): no events in small study.
cDowngraded for imprecision (-1): confidence interval includes both no effect and appreciable benefit; low numbers of events.
dDowngraded for imprecision (-1): confidence interval includes no effect and both appreciable benefit and appreciable harm; low
numbers of events.
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B A C K G R O U N D
Description of the condition
Stress urinary incontinence (SUI) is defined as the involuntary
leakage of urine associated with effort, coughing or exertion
(Abrams 2002). Mixed urinary incontinence (MUI) is the invol-
untary leakage of urine associated with urgency and also with ex-
ertion, sneezing or coughing.
Pathophysiology
Stress urinary incontinence is thought to have a complex and
multi-factorial pathophysiology that relates to general weakening
of the pelvic musculature and of collagen-dependent tissues in-
volved in pelvic support (Long 2008).
Two mechanisms are well described in the literature.
• Loss of urethral support (bladder neck hypermobility).
• Rotational descent of the proximal urethra with loss of
internal urethral integrity (urinary sphincter deficiency) as
evidenced by funnelling within the proximal urethra (Schorge
2008).
Epidemiology
An estimated 38% of women in theUnited States experience some
type of urinary incontinence (UI); SUI is the most common (
Abrams 2002; Anger 2006). It is estimated that more than 30%
of women 40 years of age or older have SUI. It has been shown
that the annual incidence of SUI increases with age and has been
reported as approximately 9% in women over 65 years of age
(Imamura 2010).
Risk factors
Major risk factors for female SUI include pregnancy, vaginal de-
livery, parity, age, postmenopausal status and obesity (MacArthur
2006; MacLennan 2000; Thom 1997). Childbearing is the main
predisposing factor specific for the development of SUI; however,
the exact mechanism is unclear.
Gynaecological surgery for prolapse, hysterectomy and other gy-
naecological procedures double the risk of SUI (Allahdin 2008;
Hampel 2004).
Diagnosis
Initial assessment of UI may include a review of the medical his-
tory, physical examination findings, a urinary diary and an in-
continence questionnaire such as the International Consultation
on Incontinence (ICI) Questionnaire-Short Form (ICIQ-SF for
Urinary Incontinence) (Avery 2004). Urodynamics is an invasive
clinical test requiring catheterisation that allows further categori-
sation of incontinence according to the underlying functional or
anatomical cause. Its use is generally limited to individuals for
whom more accurate categorisation is important (e.g. before sur-
gical treatment) (Imamura 2010).
Treatment
Treatment for UI can be divided into non-surgical and surgical
modalities. Treatment choice greatly depends on patient prefer-
ence and on additional factors such as symptom severity, degree of
interference with lifestyle, presence of related problems and degree
of co-morbidities.
Conservative and pharmacological treatment
Non-surgical treatment options for UI usually have few adverse
effects and thus are often utilised first in the treatment of UI.
Several Cochrane reviews have detailed these options, which may
include:
• lifestyle changes (weight loss, bladder training) (Wallace
2004);
• pelvic floor muscle training (PFMT) (Ayeleke 2013;
Dumoulin 2014);
• use of devices such as pessaries or vaginal cones (Herbison
2013); and
• off-label usage of pharmacological agents (oestrogen,
serotonin or noradrenaline reuptake inhibitors) (Cody 2012;
Mariappan 2005).
Surgical treatment
PreviousCochrane reviews have assessed the effects of different sur-
gical procedures performed to treat women with UI. Although the
Burch colposuspension was previously considered the “gold stan-
dard” in the treatment of female UI (Lapitan 2012), midurethral
slings are now considered the preferred treatment modality (Long
2008; Ogah 2009; Rehman 2011). Surgical treatments for women
with UI may also include:
• urethral bulking agents (Kirchin 2012);
• open or laparoscopic colposuspension (Lapitan 2012);
• suburethral slings (Ogah 2009; Rehman 2011);
• needle suspensions (Pereyra, Stamey or Raz) (Glazener
2014);
• anterior repair (Glazener 2001); and
• radiofrequency treatment.
Description of the intervention
Radiofrequency treatment
Radiofrequency ablation (RFA) is a method of heating tissue that
can cause tissue ablation and necrosis (higher temperatures) or
denatured protein (lower temperatures, 65°C to 75°C) (Takacs
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2010). Traditionally, radiofrequency treatments have been used
at high temperatures with the aim of achieving tissue necrosis.
Radiofrequency ablation, which is different from radiofrequency
collagen denaturation, has been shown to be a safe and effective
treatment option for individuals with conditions such as benign
prostatic hyperplasia (Larson 2002) and hepatic metastatic dis-
ease (Fanelli 2003). Our review will focus on the use of low-level
radiofrequency energy for localised collagen denaturation in the
treatment of female UI.
The first system to use radiofrequency energy with micro-remod-
eling was the radiofrequency treatment of the endopelvic fas-
cia, or SURx™, system (coopersurgical.com), which involved the
use of a radiofrequency probe that was inserted transvaginally
or laparoscopically into the endopelvic fascia, causing collagen
shrinkage of periurethral tissues and reduced urethral compliance
(Dmochowski 2003). The device was ultimately withdrawn by the
manufacturer because of worsening of incontinence and increased
incidence of complications such as vesicovaginal and urethrovagi-
nal fistulas; for this reason, it is not included in this review (Miller
2007a).
In 2005, Novasys Medical received US Food and Drug Admin-
istration (FDA) clearance to market transurethral radiofrequency
collagen denaturation under the trade name Renessa® in the
United States. More recently, the device used to perform this pro-
cedure has been marketed under the trade name Lyrette® by the
Verathon Company (lyretterf.com). Transurethral radiofrequency
collagen denaturation consists of a radiofrequency probe with a
palpable balloon that is placed into the proximal urethra, where
radiofrequency needles are deployed into the submucosa. Sixty-
second cycles are delivered in nine positions to a total of 36 sites
using a 21F transurethral delivery probe connected to a radiofre-
quency generator. Perceived advantages of this procedure are that
it can be done in the office setting with the patient under local
anaesthesia or intravenous sedation, without imaging, in less than
one hour. Transurethral radiofrequency collagen denaturation is
reported to be simpler than radiofrequency treatment of the en-
dopelvic fascia and is performed using a standardised technique
that is easily reproducible. It offers the additional advantage of
not requiring laparoscopic or vaginal incisions, thus reducing the
morbidity of the procedure.
How the intervention might work
Transurethral radiofrequency collagen denaturation administers
low-temperature radiofrequency energy through a transurethral
probe aimed to induce submucosal collagen denaturation while
decreasing regional tissue compliance. The decrease in regional
dynamic tissue compliance without tissue necrosis is intended to
result in functional rather than anatomical change (Takacs 2010).
Specifically, when collagen of the urethra is heated in the range
of low-temperature radiofrequency energy that is administered
by transurethral radiofrequency collagen denaturation (range of
65°C), large domains of consecutive, intramolecular hydrogen
bonds are broken, decreasing overall extensibility, and thus reduc-
ing urethral compliance (Chen 1998; Wright 2002). The maxi-
mal diameter of the urethra is reduced, stretching the surrounding
urethral muscles and allowing them to function more effectively
(Larson 2002). It is proposed that these mechanisms cause a de-
crease in funnelling and an increase in the functional length of the
urethra.
Why it is important to do this review
Transurethral radiofrequency collagen denaturation was approved
through the FDA 510(k) pre-market notification approval pro-
cess, by which new surgical devices can be approved without ad-
ditional human testing if they are substantially similar to devices
already on the market, and thus are not subject to pre-market
approval. Transurethral radiofrequency collagen denaturation of
the urethra was approved on the basis of the previous success of
RFA of metastatic liver lesions and benign prostatic hyperplasia -
very dissimilar disease processes. As a result of these low eviden-
tiary standards, considerable uncertainty remains about the true
therapeutic effectiveness and risks associated with this surgical de-
vice. In the United States, transurethral radiofrequency collagen
denaturation is being marketed directly to consumers, and indus-
try-funded studies advocate the procedure as effective, safe and
cost-effective (Sand 2014a). Although considered investigational
by many insurance providers, the procedure has a specific com-
mon procedural terminology (CPT) code (53860) to allow billing
and provider reimbursement. The company website states that
“the Lyrette Procedure is covered by Medicare in most states and
by numerous other health insurance companies” and lists physi-
cians throughout the United States who offer the procedure (lyret-
terf.com/find-a-physician). We were unable to find information
about the availability of this procedure in other countries.
To date, no study has critically assessed the quality of evidence
supporting the use of transurethral radiofrequency collagen denat-
uration, nor has any study systematically evaluated its benefits and
harms. Given the availability of multiple treatment alternatives,
the uncertain risks and the associated costs, an investigation of
the efficacy of transurethral radiofrequency collagen denaturation
appears important.
O B J E C T I V E S
To evaluate the efficacy of transurethral radiofrequency collagen
denaturation, comparedwith other interventions, in the treatment
of women with urinary incontinence (UI).
Review authors sought to compare the following.
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• Transurethral radiofrequency collagen denaturation versus
no treatment/sham treatment.
• Transurethral radiofrequency collagen denaturation versus
conservative physical treatment.
• Transurethral radiofrequency collagen denaturation versus
mechanical devices (pessaries for UI).
• Transurethral radiofrequency collagen denaturation versus
drug treatment.
• Transurethral radiofrequency collagen denaturation versus
injectable treatment for UI.
• Transurethral radiofrequency collagen denaturation versus
other surgery for UI.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel-group randomised or quasi-randomised tri-
als; we excluded cluster-randomised and cross-over trials.
Types of participants
Adult female patients with SUI or MUI diagnosed clinically or
with urodynamics.
Types of interventions
Investigators compared transurethral radiofrequency collagen de-
naturation with sham treatment, no treatment, conservative phys-
ical treatment, mechanical devices (pessaries for UI), drug treat-
ment, injectable treatment for UI or other surgery for UI.
Types of outcome measures
Measurement of outcomes assessed in this review was not a crite-
rion for inclusion.
Primary outcomes
Participant-reported measures
Number of women reporting UI symptoms after intervention at
time points defined by investigators.
Serious adverse events
Major vascular or visceral injury, bladder/urethral perforation,
nerve damage, fistula formation or other major surgical complica-
tions.
Disease-specific quality of life
Disease-specific quality of life assessed through validatedmeasures.
Secondary outcomes
Repeat continence surgery
Number of women undergoing repeat continence surgery.
Participant observations
• Overactive bladder symptoms, urgency UI.
Quantification of symptoms
• Number of pad changes.
• Pad tests (weights).
• Other quantification of symptom measures reported by
individual trials.
Clinician observations
Objective measurement of incontinence (i.e. direct observation
upon examination, leakage observed at urodynamics or other ob-
jective clinician observations of incontinence).
Other quality of life
• General health status measures (e.g. Short Form 36) (Ware
1993).
• Other quality of life measures reported by individual trials.
Surgical outcome measures
• Length of hospital stay.
• Time to return to normal activity level.
• Operative blood loss.
• Other surgical outcome measures reported by individual
trials.
Other adverse events
• Pain, dysuria.
• (New) detrusor overactivity.
• De novo urinary retention.
• Urinary tract infection.
• Haematuria.
• Dyspareunia.
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• New prolapse.
• Other adverse events reported by individual trials.
Main outcomes for ’Summary of findings’ table
• Number of women reporting UI symptoms.
• Serious adverse events.
• Disease-specific quality of life.
• Repeat continence surgery.
• Pain/dysuria.
• (New) detrusor overactivity.
• Urinary tract infection.
Search methods for identification of studies
We performed a comprehensive search on 11 January 2014 that
was rerun on 19 December 2014 for both published and unpub-
lished studies without language or other restrictions.We employed
both electronic and manual searches.
Electronic searches
We searched the Cochrane Incontinence Group Specialised Reg-
ister (for details, see Appendix 1), EMBASE and EMBASE Clas-
sic via Ovid SP (for search strategy, see Appendix 2) and Google
Scholar (see Appendix 3) to identify relevant trials. We contacted
manufacturers for information on relevant trials. We searched
the FDA website (www.fda.gov/MedicalDevices/default.htm; see
Appendix 4) for additional relevant documents or studies leading
to approval of transurethral radiofrequency collagen denaturation.
We applied no language or other restrictions. For studies identi-
fied, we contacted study authors and/or sponsors to clarify infor-
mation or to request additional data points, as necessary.
In addition, we searched the following clinical trials registries.
• Current Controlled Trials: www.controlled-trials.com (see
Appendix 5).
• ClinicalTrials.gov: www.clinicaltrials.gov (see Appendix 6).
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP): www.who.int/ictrp/en (see
Appendix 7).
Searching other resources
We scrutinised the reference lists of identified relevant studies
for additional citations. We contacted specialists in the field to
ask for possible unpublished data. In addition, we searched for
unpublished studies by handsearching abstract proceedings from
the 2003 to 2014 annual meetings of the American College of
Obstetricians and Gynecologists (ACOG), American Urological
Association (AUA), International Urogynecological Association
(IUGA), European Association of Urology (EAU), American As-
sociation of Gynecologic Laparoscopists AdvancingMinimally In-
vasive Gynecology Worldwide (AAGL) and International Conti-
nence Society (ICS). We manually searched abstract proceedings
of the American Urogynecologic Society (AUGS) for the years
2007 to 2014.
Data collection and analysis
Selection of studies
Two review authors (DK and JH) independently screened the trials
for eligibility. They consulted a third review author (MLM or
PD) when there was disagreement, which was also recorded. They
obtained full-text articles of eligible studies and listed studies that
were formally considered for the review but were excluded along
with reasons for their exclusion.
Data extraction and management
Studies that met the inclusion criteria passed to the stage of data
abstraction. Two review authors (DK and JH) independently con-
ducted data abstraction using a standardised data abstraction form,
which had been pilot-tested. Extracted data included study design;
dates when the study was conducted; setting; participant inclusion
and exclusion criteria; participant age; sample size of the study
and of each intervention group; details of interventions; details
of outcomes relevant to the review including how measured, time
points at which they were measured and outcomes data; details
of funding sources; declarations of interest among primary study
authors; and study details relevant to risk of bias assessment. Anal-
ysis was based on available data from included trials relevant to
comparisons and outcomes of interest. Review authors presented
and considered data according to the comparisons and grouped
them by outcomes. They resolved differences of opinion related
to data abstraction by consensus and/or through discussion with
a third review author (MLM or PD).
Assessment of risk of bias in included studies
Two review authors (DK and JH) evaluated all relevant clinical
studies independently to assess methodological quality. They re-
solved disagreements by discussion with a third review author
(MLM or PD). Each review author undertook assessment of
methodological quality using the tool for assessing risk of bias of
The Cochrane Collaboration (Higgins 2011a). We assessed the
following domains as having low, unclear or high risk of bias.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective reporting.
• Other sources of bias.
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We assessed blinding of participants and personnel, blinding of
outcome assessment and incomplete outcomedata on anoutcome-
specific basis, as the risk of bias of each of these domains is likely
to vary by outcome.
We grouped outcomes as subjective and objective for outcome-
specific risk of bias assessments in blinding domains. For the three
primary outcomes, we considered the number of women report-
ing UI symptoms and disease-specific quality of life as subjective
outcomes, whereas we categorised occurrence of a serious adverse
event as an objective outcome.
We rated as subjective all secondary outcomes except for quantifi-
cation of symptoms (e.g. number of pad changes), length of hos-
pital stay, operative blood loss, occurrence of haematuria, urinary
tract infection, urinary retention, repeat continence surgery, new
prolapse and objective measurement of incontinence (e.g. change
in leak point pressure).
For the incomplete outcome data domain, we grouped outcomes
that had similar circumstances related to completeness of data.
Measures of treatment effect
We analysed the extracted data using Review Manager software
(RevMan 2014). For dichotomous variables, we extracted num-
bers of events and totals to calculate risk ratios (RRs) and 95%
confidence intervals (CIs). If numbers of events were unavailable,
we used reported percentages of participants experiencing the out-
come and total numbers of participants assessed to calculate the
numbers of events. For continuous outcomes, we extracted means,
standard deviations and totals to calculatemean differences (MDs)
and 95% CIs.
Unit of analysis issues
We included only randomised and quasi-randomised controlled
trials; we excluded cluster-randomised and cross-over trials. Al-
though they were eligible for inclusion, we identified no studies
with multiple intervention groups.
Dealing with missing data
We contacted the original investigators to request missing data
so we could analyse all data by performing an intention-to-treat
(ITT) analysis. However, we obtained no additional data. We
therefore based analyses on available data only.We identified non-
ITT analyses in the Results section as available case analyses ac-
cordingly.
Assessment of heterogeneity
Weplanned to assess heterogeneity by visually inspecting the forest
plots and by using the I2 statistic (Higgins 2002; Higgins 2003).
We defined the thresholds for interpretation of the I2 statistic ac-
cording to the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Deeks 2011): < 30% heterogeneity may not be impor-
tant, 30% to 50% may represent moderate heterogeneity and >
50% may represent substantial/considerable heterogeneity. Het-
erogeneity was not a factor because of the number of studies in-
cluded in the review.
Assessment of reporting biases
Tominimise the impact of possible publication bias, we conducted
electronic and manual searches of multiple databases, including
registries, without language restriction, to identify published and
unpublished studies. Fewer than 10 studies were available; there-
fore we did not conduct a test for funnel plot asymmetry to assess
potential publication bias. We attempted to obtain study proto-
cols to assess for reporting bias.
Data synthesis
We planned to pool data from eligible studies to estimate a pooled
effect size and to generate the corresponding forest plots. We
planned to perform meta-analysis using a random-effects model
with theMantel-Haenszel method for dichotomous data and with
the inverse variancemethod for continuous data. Given that only a
single eligible trial was identified, we conducted no meta-analysis.
Subgroup analysis and investigation of heterogeneity
If relevant data were available (subgroups already stratified in the
study), we planned to explore the following potential sources of
heterogeneity using subgroup analyses based on four a priori de-
fined hypotheses (with prespecified direction) and to perform ad-
ditional testing for interaction.
• Participant age (50 years of age vs older; better outcomes in
younger participants).
• Menopausal status (before vs after; better outcomes in
premenopausal women).
• Presence or absence of prolapse (yes vs no; better outcomes
when prolapse was absent).
• History of prior surgical procedure for treatment of
individuals with UI (yes vs no; better outcomes with no prior
surgical procedure).
Given that limited data were identified, none of the prespecified
subgroup analyses were possible. We report a post hoc subgroup
analysis performed by degree of baseline UI (mild vs moderate to
severe), as provided by the trial investigators.
Sensitivity analysis
We planned to investigate the robustness of results by performing
a sensitivity analysis based on methodological quality as defined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b) and to report the results in a summary table.
Given the paucity of data, we performed no sensitivity analysis.
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’Summary of findings’ table
We rated the overall quality of evidence using the GRADE frame-
work, with consideration of study limitations (risk of bias), in-
consistency, indirectness, imprecision and publication bias, and
we presented this information in a ’Summary of findings’ table
(Guyatt 2008; Guyatt 2011; Schünemann 2011).
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
For this review, we identified 253 records through the search and
retrieved 28 full-text articles; of these, we excluded 25 reports of
21 studies and provided reasons in the Characteristics of excluded
studies table. None of the abstracts or presentations provided ad-
ditional relevant trial data that met our study inclusion criteria.
One study met eligibility criteria and was included (Appell 2006).
See Figure 1 for a flow diagram of the search.
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Figure 1. Study flow diagram.
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Included studies
We included in the analysis one sham-controlled randomised trial
in women with SUI conducted in the United States of America
(Appell 2006). In this study, 110 women underwent transurethral
radiofrequency collagen denaturation in the treatment arm and 63
underwent sham treatment in the control arm. Mean participant
age was 50 years (range 22 to 76 years), and mean duration of SUI
was eight years (range one to 49 years). All participantswere treated
with the same type of radiofrequency probe (Novasys Medical,
Inc., Newark, California) and one of two similar radiofrequency
generators (NovasysMedical, Inc.; CuronMedical, Inc., Fremont,
California; Appell 2006).
Incontinence quality of life (I-QOL) score improvement of 10 or
more points and change in leak point pressure (LPP) were assessed
at sixmonths and12months of follow-up to look for improvement
among the two groups. Adverse events and postoperative level of
discomfort were also assessed. The study was funded by a grant
fromNovasys Medical, Inc., the manufacturer of the transurethral
radiofrequency collagendenaturationdevice at that time. Formore
information, see Characteristics of included studies.
Excluded studies
We excluded 21 studies after performing full-text assessment for
eligibility.
We excluded four studies because they were observational studies
of single-armed cohorts (Elser 2009; Lenihan 2005; Sotomayor
2003; Wells 2007). Of these four observational studies, two were
original cohort studies that assessed the primary outcome of this
review (Elser 2009; Sotomayor 2003) and two did not assess the
primary outcome of the systematic review (Lenihan 2005; Wells
2007). One study performed a cost analysis of transurethral ra-
diofrequency collagen denaturation (Sand 2014b). Another study
was an ongoing multi-centre prospective single-armed trial of
transurethral collagen denaturation funded by the Verathon Cor-
poration to study the Lyrette® device (Lukban 2013a). Results at
12 months of follow-up have been presented at society meetings
as abstracts without a full-text study report (Lukban 2013a). As
a single-armed study, this trial did not meet inclusion criteria for
this review. For more information, see Characteristics of excluded
studies.
We identified no studies comparing the efficacy of transurethral
radiofrequency collagen denaturation versus conservative physical
treatment, use of mechanical devices (such as a pessary), drug
treatment, injectable treatment or other surgery for UI.
Risk of bias in included studies
We assessed risk of bias on an outcome-specific basis.
Allocation
Random sequence generation
The trial used a computer-generated allocation sequence with a 2:
1 ratio. We judged risk of bias to be low for all outcomes.
Allocation concealment
Allocation concealment was not reported. We rated risk of bias as
unclear for all outcomes.
Blinding
We grouped outcomes as subjective and objective for outcome-
specific risk of bias assessments in blinding domains.
Blinding of participants and personnel
Although participants were reported to be blinded using a sham
design, the study did not report blinding of study personnel. As
blinding of personnel was not reported, we judged the risk of
performance bias to be unclear for both subjective and objective
outcomes.
Blinding of outcome assessment
Blinding of outcome assessors was not reported in the included
study. We rated the risk of bias as low for objective outcomes and
as unclear for subjective outcomes.
Incomplete outcome data
We grouped categories of outcomes that had similar circumstances
related to completeness of data for outcome-specific assessment of
the incomplete outcome data risk of bias domain.
At 12 months, 82% of the enrolled population were evaluated
for ≥ 10-point I-QOL score improvement. Twenty-one women
(12%) were lost to follow-up, and eight women had changes in
their medical history that excluded them from the study (hysterec-
tomy or urinary tract infection (UTI) at 12 months). As UTI was
an adverse event evaluated in the study, the completeness of data
for this primary subjective outcome is questionable. Two women
had baseline I-QOL scores > 90 and therefore could not have a
≥ 10-point improvement. The percentage of participants in each
group who were lost to follow-up or were otherwise considered
unevaluable and excluded from analysis was similar. We judged
risk of bias for this disease-specific quality of life outcome to be
high.
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The included study assessed changes in LPP among participants;
however only 78.6% were evaluated. A similar percentage of par-
ticipants in each group was lost to follow-up or was otherwise con-
sidered unevaluable and was excluded from analysis. Risk of bias
was rated as high for this objective measurement of incontinence.
For other outcomes reported in the included study, completeness
of outcome datawas not reported.We judged risk of bias as unclear
for these outcomes.
Selective reporting
In theMethods section, trial investigators reported that the study’s
main outcomes (≥ 10-point I-QOL score improvement and
change in LPP) were assessed at six months and at 12 months;
however, no six-month data were presented. We therefore rated
the study to be at high risk for selective reporting.
Other potential sources of bias
Investigators provided a subgroup analysis that stratified partici-
pants as having mild versus moderate/severe UI at baseline. No
trial protocol was available, and investigators provided no ratio-
nale for the grouping. We rated this analysis as having high risk of
bias and the positive findings as at risk for being spurious.
Effects of interventions
See: Summary of findings for the main comparison
Transurethral radiofrequency collagen denaturation compared
with no treatment/sham treatment for women with UI
Transurethral radiofrequency collagen denaturation
versus no treatment/sham treatment
Primary outcomes
Participant-reported measures
Number of women reporting UI symptoms after intervention
at time points defined by investigators
We found no data reported for this outcome measure (Summary
of findings for the main comparison).
Serious adverse events
Major vascular or visceral injury, bladder/urethral
perforation, nerve damage, fistula formation or other major
surgical complications
No serious adverse events were recorded in the treatment group
or the control group during the 12-month trial (one study; 173
participants; Analysis 1.1), although the trial authors did not de-
fine ’serious adverse event’. Risk of bias was high and imprecision
was a matter of concern for this outcome; the GRADE quality of
the evidence was downgraded by two levels to low (Summary of
findings for the main comparison).
Disease-specific quality of life
Disease-specific quality of life assessed through validated
measures
Transurethral radiofrequency collagen denaturation was not asso-
ciated with an increase in the number of women with an I-QOL
score improvement greater than or equal to 10 points at 12months
when compared with sham treatment in an analysis of available
data (RR 1.11, 95% CI 0.77 to 1.62; participants = 142; studies
= 1; Analysis 1.2; Figure 2). We downgraded the quality of the
evidence by two levels to low because of high risk of bias and im-
precision (Summary of findings for the main comparison).
Figure 2. Forest plot of comparison: 1 Transurethral radiofrequency collagen denaturation versus no
treatment/sham treatment, outcome: 1.2 Disease-specific quality of life: number of women with an I-QOL
score improvement greater than or equal to 10 points at 12 months.
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Secondary outcomes
Repeat continence surgery
Number of women undergoing repeat continence surgery
We found no available evidence for this outcome (Summary of
findings for the main comparison).
Participant observations
Overactive bladder symptoms, urgency UI
We found no available evidence for this outcome.
Quantification of symptoms
Number of pad changes
We found no available evidence for this outcome.
Pad tests (weights)
We found no available evidence for this outcome.
Other quantification of symptom measures reported by
individual trials
We found no available evidence for this outcome.
Clinician observations
Objective measurement of incontinence (such as direct
observation upon examination, leakage observed at
urodynamics or other objective clinician observations of
incontinence)
Mean change in LPP at 12 months was -13.2 ± 39.2 cm H2O in
women in the treatment arm and 2.0 ± 33.8 cm H2O in women
in the sham treatment arm, with a lower mean representing a
better outcome. In an analysis of available data at 12 months,
mean LPP change was significantly improved in the transurethral
radiofrequency collagen denaturation group (MD -15.20, 95%
CI -27.75 to -2.65; participants = 136; studies = 1; Analysis 1.3;
Figure 3), with aMD less than zero favouring the treatment group.
However, the effects were uncertain because evidence was of very
low quality as the result of high risk of bias, indirectness and
imprecision.
Figure 3. Forest plot of comparison: 1 Transurethral radiofrequency collagen denaturation versus no
treatment/sham treatment, outcome: 1.3 Clinician observations: objective measurement of incontinence:
change in leak point pressure at 12 months.
Other quality of life
General health status measures (e.g. Short Form 36)
We found no available evidence for this outcome.
Other quality of life measures reported by individual trials
We found no available evidence for this outcome.
Surgical outcome measures
Length of hospital stay
We found no available evidence for this outcome.
Time to return to normal activity level
We found no available evidence for this outcome.
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Operative blood loss
We found no available evidence for this outcome.
Other surgical outcome measures reported by individual trials
The one included study (participants = 173) reported that the level
of postoperative discomfort as assessed on a visual analogue scale
from0 (no pain) to 10 (terrible pain) was not significantly different
in the treatment arm versus the control arm. However, control
group data were not available to the review authors to allow for
calculation of the effect estimate and the confidence interval. The
quality of the evidence was very low as the result of very serious
study limitations and imprecision.
Other adverse events
Pain, dysuria
Dysuria occurred in 9.1% of actively treated participants and in
1.6% of sham-treated participants (RR 5.73, 95% CI 0.75 to
43.70; participants = 173; studies = 1; Analysis 1.4; Figure 4).
The quality of the evidence was downgraded by two levels to low
because of high risk of bias and imprecision (Summary of findings
for the main comparison).
Figure 4. Forest plot of comparison: 1 Transurethral radiofrequency collagen denaturation versus no
treatment/sham treatment, outcome: 1.4 Other adverse event: pain/dysuria: dysuria.
(New) detrusor overactivity
Dry overactive bladder was more common in the transurethral
radiofrequency collagen denaturation arm (7.3% vs 3.2%), but
this finding was not statistically significant. Very little difference in
the prevalence of wet overactive bladder was noted between groups
(10% vs 9.5%). When we combined the dry overactive bladder
data and the wet overactive bladder data, we found no evidence
of a difference in effect on overactive bladder symptoms between
groups (RR 1.36, 95%CI 0.63 to 2.93; participants = 173; studies
= 1; Analysis 1.5). We downgraded the quality of the evidence to
low as the result of high risk of bias and imprecision (Summary of
findings for the main comparison).
De novo urinary retention
Urinary retention occurred rarely: One participant in the treat-
ment arm developed urinary retention, and it was unclear as to
whether this was of new onset (RR 1.73, 95% CI 0.07 to 41.84;
participants = 173; studies = 1; Analysis 1.6; Figure 5). We judged
the quality of the evidence as low because of high risk of bias and
imprecision.
Figure 5. Forest plot of comparison: 1 Transurethral radiofrequency collagen denaturation versus no
treatment/sham treatment, outcome: 1.6 Other adverse event: de novo urinary retention: urinary retention.
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Urinary tract infection
Urinary tract infection was observed to occur equally when treat-
ment was compared with sham treatment (4.5% vs 4.8%, respec-
tively), and the results were not statistically significant (RR 0.95,
95% CI 0.24 to 3.86; participants = 173; studies = 1; Analysis
1.7). The quality of the evidence was low as the result of down-
grades for high risk of bias and imprecision (Summary of findings
for the main comparison).
Haematuria
One participant in the treatment arm developed haematuria
(0.9%), but this finding was not statistically significant (RR 1.73,
95% CI 0.07 to 41.84; participants = 173; studies = 1; Analysis
1.8; Figure 6). Further research is very likely to change the effect
estimate because low-quality evidence was downgraded for high
risk of bias and imprecision.
Figure 6. Forest plot of comparison: 1 Transurethral radiofrequency collagen denaturation versus no
treatment/sham treatment, outcome: 1.8 Other adverse event: haematuria.
Dyspareunia
We found no available evidence for this outcome.
New prolapse
We found no available evidence for this outcome.
Other adverse events reported by individual trials
Hesitancy was reported by one participant in the sham treatment
arm (1.6%) and by no participants in the treatment arm (0%),
but this finding was not statistically significant (RR 0.19, 95% CI
0.01 to 4.65; participants = 173; studies = 1; Analysis 1.9). High
risk of bias and imprecision resulted in downgrading of the quality
of the evidence to low.
Subgroup analyses
Given the absence of data, we were unable to perform subgroup
analyses based on the pre-identified prognostic variables, which
included participant age, menopausal status, presence or absence
of prolapse and history of prior surgical procedure for UI.
In an available case subgroup analysis not prespecified in this re-
view, investigators groupedparticipants on the basis of their level of
baseline incontinence into ’mild’ and ’moderate to severe’ groups.
In women with mild incontinence, the RR when treatment was
compared with sham treatment for the outcome of number of
women with an I-QOL score improvement greater than or equal
to 10 points at 12 months was 0.63 (95% CI 0.29 to 1.37; P
value 0.24; participants = 69; studies = 1; analysis not shown). In
women with moderate to severe incontinence, the RR was 1.49
(95% CI 1.00 to 2.22; P value 0.05; participants = 73; studies =
1; analysis not shown). In these subgroups, according to baseline
incontinence, the GRADE quality of the evidence was very low
because of downgrading by two levels for high risk of bias and by
one level for imprecision. No data were available to permit the
same subgroup analyses for other outcomes.
Transurethral radiofrequency collagen denaturation
versus conservative physical treatment
We found no available evidence for this comparison.
Transurethral radiofrequency collagen denaturation
versus mechanical devices (pessaries for UI)
We found no available evidence for this comparison.
Transurethral radiofrequency collagen denaturation
versus drug treatment
We found no available evidence for this comparison.
17Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Transurethral radiofrequency collagen denaturation
versus injectable treatment for UI
We found no available evidence for this comparison.
Transurethral radiofrequency collagen denaturation
versus other surgery for UI
We found no available evidence for this comparison.
D I S C U S S I O N
Summary of main results
We systematically reviewed the quality of existing evidence on
transurethral radiofrequency collagen denaturation for the treat-
ment of female UI. Only one small sham-controlled randomised
trial, which enrolled women with SUI, met inclusion criteria for
this systematic review (Appell 2006).
The trial did not report any evidence with regards to the impact of
transurethral radiofrequency collagen denaturation on one of the
primary outcomes of the review - the number of women reporting
UI symptoms (Summary of findings for the main comparison).
The trialists reported that no serious adverse events occurred in
either the treatment arm or the control arm of the trial (Summary
of findings for the main comparison), but the trial was small
and further research is likely to change the estimate. In the in-
cluded study, investigators found no statistically significant dif-
ferences in disease-specific quality of life, as measured by the
number of women with an I-QOL score improvement greater
than or equal to 10 points, between the women who underwent
transurethral radiofrequency collagen denaturation and those who
underwent sham treatment at 12months (Summary of findings for
the main comparison). However, the trial was small and the confi-
dence intervals wide. The study reported no evidence with regards
to the number of women undergoing repeat continence surgery
(Summary of findings for themain comparison). The trial was too
small to reliably detect differences between groups in the occur-
rence of other adverse events, such as pain/dysuria, (new) detrusor
overactivity, urinary tract infection, urinary retention, haematuria
or hesitancy (Summary of findings for the main comparison).
We found no trials of comparisons between transurethral radiofre-
quency collagendenaturation and conservative physical treatment,
mechanical devices, drug treatment, injectable treatment for UI
or other surgery for UI.
Overall completeness and applicability of
evidence
This review highlighted substantial gaps in the evidence, as we
were unable to find any studies comparing transurethral radiofre-
quency collagen denaturation versus five of the predefined types of
comparators: conservative physical treatment, mechanical devices,
drug treatment, injectable treatment and other surgery for UI.
One randomised controlled trial comparing transurethral radiofre-
quency collagen denaturation versus sham treatment was system-
atically reviewed. The single included study did not assess our
previously stated primary outcome of the number of women re-
porting UI symptoms after treatment. The one comparison study
analysed did not address a number of our secondary outcomes,
including the need for further incontinence procedures, dyspare-
unia and new prolapse development.
The trial involved both academic and community urologists and
urogynaecologists, thereby enhancing the generalisability of its
findings. The most noteworthy exclusion criterion limiting appli-
cability was the exclusion of women with pre-existing overactive
bladder symptoms and/or documentation of bladder overactivity.
Also, SUI was the only form of UI examined in the trial. Women
who had undergone any prior procedure for UI were excluded.
Quality of the evidence
With regards to the primary outcomes of this review, no ran-
domised trial evidence was found to inform our understanding of
the impact of transurethral radiofrequency collagen denaturation
on individual, patient-reported symptoms of UI. The quality of
evidence for the absence of treatment-associated serious adverse
events was rated as low, mainly because of concerns over risk of
bias and imprecision. The quality of evidence for the outcome of
disease-specific quality of life was rated as low because of risk of
bias and imprecision. Of particular concern with respect to risk of
bias was the failure of study authors to account for all participants
in the outcome analysis.
We found no evidence for the secondary,main outcome of number
of women undergoing repeat continence surgery. The quality of
evidence for the other secondary, patient-reported main outcomes
was rated as low according to GRADE. We downgraded for risk
of bias as well as imprecision.
Consideration of inconsistency, indirectness and publication bias
did not result in any further downgrading of the quality of evidence
for the main outcomes.
Overall, the quality of the body of evidence contributing to the
comparison of transurethral radiofrequency collagen denaturation
versus sham treatment in this review was low, and evidence was
lacking for the other five predefined comparisons.
Potential biases in the review process
Our risk of bias assessment was based on the full-text publication
of the study by Appell et al (Appell 2006) and the methodolog-
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ical detail it provided; however, the actual methodological qual-
ity of the published study may have been better than reported
(Devereaux 2004). Unfortunately, attempts to obtain further in-
formation from the principal investigator were limited by his re-
cent passing. The recent change in the company that markets the
device in the United States to perform this surgical procedure
may have been an additional barrier towards acquiring additional
information. We contacted the manufacturer and the secondary
authors of the study but received no additional information that
would change our assessment of the methodological quality of the
study.
Agreements and disagreements with other
studies or reviews
A technology assessment and review of the literature on
transurethral radiofrequency collagen denaturation was published
by theCalifornia Technology Assessment Forum in 2008 (Karliner
2008). It does not include several studies that were published after
that time period, but it does include an analysis on themodality of
laparoscopic and transvaginal radiofrequency denaturation, which
has since been withdrawn from the market and was not within the
scope of this Cochrane review.
A narrative review on transurethral radiofrequency collagen de-
naturation was published in 2012 (Lukban 2012b). However, it
did not apply established systematic review methodology, which
includes a comprehensive search for both published and unpub-
lished studies and a critical appraisal of the quality of evidence, as
was applied in this Cochrane review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This systematic review questions the therapeutic efficacy of
transurethral radiofrequency collagen denaturation to treat female
UI. The included trial was too small to detect any rare serious
adverse events, and we were unable to establish the impact of this
approach on individual patient-reported UI symptoms. Evidence
was insufficient to detect a difference in disease-specific quality of
life when compared with sham treatment, and we are uncertain of
the findings because the quality of the evidence was low.
Effects of transurethral radiofrequency collagendenaturation com-
pared with conservative physical treatment, mechanical devices,
drug treatment, injectable treatment for UI or other surgery for
UI are unclear, as we found no available evidence to inform these
comparisons.
Implications for research
The findings of this reviewwere based on a single, sham-controlled
randomised trial at high risk of bias that did not address patient-
reported symptoms of UI. Before this intervention is made avail-
able to women, more rigorous and adequately powered trials are
required to assess the relative benefits and adverse event profile of
transurethral radiofrequency collagen denaturation as compared
with otherminimally invasive, active treatment options such as use
of a urethral bulking agent injection or suburethral slings. These
trials should be carefully designed and executed with a focus on pa-
tient-important outcomes, transparently reported and adequately
powered to provide definitive results.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Appell 2006
Methods Study design: parallel-group, sham-controlled randomised trial; 2:1 randomisation
Study dates: Participants were reported to have been enrolled between March 2003 and
September 2003 in the primary study publication; however, these dates were reported as
March 2002 to September 2002 in 2 related articles; length of follow-up = 12 months
Setting: multi-centre trial performed at 10 sites in the United States
Participants Inclusion criteria: SUI diagnosed by patient history and witnessed SUI on physical exam,
bladder outlet hypermobility on physical exam and baseline leak point pressure ≥ 60
cm H2O
Exclusion criteria: evidence of detrusor overactivity on cystometrogram, post-void resid-
ual > 50 cc, history of dry or wet overactive bladder, previous surgery or bulking agent
therapy and significant stage IV pelvic organ prolapse
Sample size: 173 participants enrolled
Age: mean 50 years (range 22 to 76 years)
UI duration: mean 8 years (range 1 to 49 years)
Note: Women with a change in medical condition such as hysterectomy or urinary tract
infection were excluded from the final analysis of incontinence quality of lIfe at 12
months
Interventions Transurethral radiofrequency collagen denaturation (n = 110): A 21 French transurethral
micro-remodeling probe was used and was connected to a radiofrequency generator. All
participants were treated with the same type of radiofrequency probe (Novasys Medical,
Inc., Newark, California) and 1 of 2 similar types of radiofrequency generator (Novasys
Medical, Inc.; CuronMedical, Inc., Fremont, California). After passage into the bladder,
a balloon on the probe tip was insufflated to anchor the probe within the bladder
outlet. Four 23-gauge needle electrodes were deployed into the urethral submucosa,
and radiofrequency was delivered for 60-second intervals. The probe was rotated after
each interval until the needles were placed in 9 different positions within the urethra (9
minutes total)
Sham treatment (n = 63): Sham treatment also utilised a transurethral probe; however
the probe lacked needle electrodes, and the radiofrequency generator was modified so
no energy was delivered but the generator appeared and sounded as though energy were
being delivered
Outcomes Serious adverse events
How measured: All adverse events were recorded; no definition of ’serious adverse event’
was provided
Time points measured: at 1 week, 1 month, 3 months, 6 months and 12 months
Time points reported: 12-month prevalence
Subgroups: no subgroups reported
Disease-specific quality of life
How measured: 10-Point or greater improvement in Incontinence Quality of Life (I-
QOL) score
Time points measured: at 6 months and at 12 months
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Appell 2006 (Continued)
Time points reported: at 12 months
Subgroups: post hoc subgroup analysis according to level of UI at baseline (mild vs
moderate to severe)
Clinician observations: objective measurement of incontinence: change in leak
point pressure
How measured: mean change in leak point pressure testing
Time points measured: at 6 months and at 12 months
Time points reported: at 12 months
Subgroups: no subgroups reported
Surgical outcomemeasures: other surgical outcomemeasures reported by individual
trials: level of postoperative discomfort
How measured: participant-reported level of postoperative discomfort as assessed on a
visual analogue scale from 0 (no pain) to 10 (terrible pain)
Time points measured: immediately before discharge
Time points reported: immediately before discharge; however, no data were reported
for the sham treatment group except that the mean was not statistically significantly
different from that of the transurethral radiofrequency collagen denaturation group
Subgroups: No subgroups were reported
Other adverse events: pain/dysuria
How measured: dysuria - all adverse events were recorded
Time points measured: at 1 week, 1 month, 3 months, 6 months and 12 months
Time points reported: 12-month prevalence
Subgroups: no subgroups reported
Other adverse events: (new) detrusor overactivity: overactive bladder symptoms
How measured: All adverse events were recorded
Time points measured: at 1 week, 1 month, 3 months, 6 months and 12 months
Time points reported: 12-month prevalence
Subgroups: No subgroups were reported
Note: Dry overactive bladder and wet overactive bladder data were reported separately
in the study; however in the review we combined the numbers of events to assess the
outcome overactive bladder symptoms
Other adverse events: de novo urinary retention
How measured: All adverse events were recorded
Time points measured: at 1 week, 1 month, 3 months, 6 months and 12 months
Time points reported: 12-month prevalence
Subgroups: No subgroups were reported
Note: unclear whether the events reported were of new onset
Other adverse events: urinary tract infection
How measured: All adverse events were recorded
Time points measured: at 1 week, 1 month, 3 months, 6 months and 12 months
Time points reported: 12-month prevalence
Subgroups: No subgroups were reported
Other adverse events: haematuria
How measured: All adverse events were recorded
Time points measured: at 1 week, 1 month, 3 months, 6 months and 12 months
Time points reported: 12-month prevalence
Subgroups: No subgroups were reported
Other adverse events: other adverse events reported by individual trials: hesitancy
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Appell 2006 (Continued)
How measured: All adverse events were recorded
Time points measured: at 1 week, 1 month, 3 months, 6 months and 12 months
Time points reported: 12-month prevalence
Subgroups: No subgroups were reported
Funding Source Grant sponsored by Novasys Medical, Inc
Declarations of Interest No conflicts of interest were reported by study authors
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subjects were prospectively ran-
domized”
Quote: “Computer-generated randomiza-
tion targeted a 2:1 treatment to sham treat-
ment arm ratio”
Comment: Computer randomisation was
used and was found to be adequate
Allocation concealment (selection bias) Unclear risk Comment: Allocation concealment was
not reported
Blinding of participants and personnel
(performance bias)
Subjective outcomes
Unclear risk Quote: “Subjects [...] remained blinded
through the 12 months duration of the
trial”
Quote: “the sham treatment RF generator
was modified so that no RF was actually
delivered, although the generator appeared
and sounded as if RF was being delivered”
Comment: Participants were blinded as to
whether they received treatment or sham
treatment, but blinding of study personnel
was unclear
Blinding of participants and personnel
(performance bias)
Objective outcomes
Unclear risk Quote: “Subjects [...] remained blinded
through the 12 months duration of the
trial”
Quote: “the sham treatment RF generator
was modified so that no RF was actually
delivered, although the generator appeared
and sounded as if RF was being delivered”
Comment: Participants were blinded as to
whether they received treatment or sham
treatment, but blinding of study personnel
was unclear
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Appell 2006 (Continued)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Unclear risk Comment: Itwas unclearwhether outcome
assessors were blinded
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Comment: Although blinding of outcome
assessors was unclear, risk of bias for objec-
tive outcomes was judged as low
Incomplete outcome data (attrition bias)
Disease-specific quality of life
High risk Quote: “At 12months, the evaluable popu-
lation for the quality of life outcome analy-
sis included 142 women (82% of enrolled)
, 89 in the treatment (80.1%) and 53 in
the sham treatment (84.1%) arm (1.7:1 ra-
tio). The two evaluable population arms
did not statistically significantly differ for
mean age, mean SUI duration, mean body
mass index, menopausal status, mean base-
line LPP, or mean baseline I-QOL score.
Analysis did not include 12months I-QOL
data from 21 women who were lost to fol-
low-up, 8 women whose change in I-QOL
(either favorable or unfavorable) could not
clearly be attributed to the treatment or
sham treatment due to a change in medical
history (hysterectomy during the trial pe-
riod, urinary tract infection at 12 months,
etc.), and two women whose baseline I-
QOL scores were > 90 points and who,
therefore, could not numerically achieve≥
10 point score improvement”
Comment: For the I-QOL outcome, 21 of
110 (19.1%) and 10 of 63 (15.9%) partic-
ipants in the treatment and control arms,
respectively, were lost to follow-up or were
otherwise considered unevaluable and were
excluded fromanalysis. Although these per-
centages were similar across groups, it was
unclear whether the reasons for missing
data were balanced across groups. Risk of
bias was judged to be high
Incomplete outcome data (attrition bias)
Objective measurement of incontinence
High risk Quote: “At 12 months, the evaluable pop-
ulation for the LPP analysis included 136
women (78.6%of enrolled), 87 in the treat-
ment (79.1%) and 49 in the sham treat-
ment (77.8%) arm (1.8:1 ratio). The two
evaluable population arms did not statis-
tically significantly differ for mean age,
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Appell 2006 (Continued)
mean SUI duration, mean body mass in-
dex, menopausal status, mean baseline I-
QOL score, or mean baseline LPP. Anal-
ysis did not include 12 months LPP data
from 21 women who were lost to follow-
up, 6 women whose change in LPP (either
increase or decrease) could not clearly be
attributed to the treatment or sham treat-
ment due to a change in medical history
(such as the performance of a hysterectomy
during the trial period), and 10 women
whose LPP performance parameters vio-
lated trial protocol guidelines”
Comment: For the LPP assessment, 23 of
110 (20.9%) and 14 of 63 (22.2%) partic-
ipants in the treatment and control arms,
respectively, were lost to follow-up or were
otherwise considered unevaluable and were
excluded fromanalysis. Although these per-
centages were similar across groups, it was
unclear whether the reasons for missing
data were balanced across groups. Risk of
bias was judged to be high
Incomplete outcome data (attrition bias)
Serious adverse events; other surgical out-
come measures reported by individual tri-
als; other adverse events
Unclear risk Comment: We judged the completeness of
outcomes data for these outcomes to be
unclear. Participants were lost to follow-
up or were otherwise considered unevalu-
able and were excluded from analysis of
other outcomes; therefore outcomes data
may have also been incomplete for seri-
ous adverse events, other surgical outcome
measures and other adverse event outcomes
Selective reporting (reporting bias) High risk Comment: Outcomes at 6 months of fol-
low-up were not reported. For the postop-
erative level of discomfort outcome, data
were reported for the RF treatment group
but not for the sham treatment group,
although the study authors reported no
statistically significant differences between
groups
Other bias High risk Comment: Investigators reported a post
hoc subgroup analysis that grouped par-
ticipants according to their baseline degree
of incontinence as ’mild’ versus ’moderate
to severe’. Results of this subgroup analysis
were judged to be at high risk of bias
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I-QOL = Incontinence Quality of Life; LPP = leak point pressure; RF = radiofrequency; SUI = stress urinary incontinence; UI = urinary
incontinence.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Appell 2007 Not a randomised or quasi-randomised trial; a review paper
Appell 2008 Not a randomised or quasi-randomised trial; a review paper
Crivellaro 2009 Not a randomised or quasi-randomised trial; a review paper
Davila 2011 Not a randomised or quasi-randomised trial; a review paper
Dillon 2009 Not a randomised or quasi-randomised trial; a review paper
Dmochowski 2002 Not a randomised or quasi-randomised trial; a review paper
Edelstein 2006 Non-human participants
Elser 2007 Not a randomised or quasi-randomised trial; a review paper
Elser 2009 Not a randomised or quasi-randomised trial; 12-month, 18-month and 36-month follow-up results from a
prospective, 36-month, open-label, single-arm clinical trial
Gilleran 2005 Not a randomised or quasi-randomised trial; a review paper
Juma 2007 Not a randomised or quasi-randomised trial; a review paper
Lenihan 2005 Not a randomised or quasi-randomised trial; an open-label pilot clinical trial looking at the use of oral plus
local anaesthesia while transurethral radiofrequency collagen denaturation is performed in an office setting
Lukban 2012a Not a randomised or quasi-randomised trial; a review paper
Lukban 2013a Not a randomised or quasi-randomised trial; a single-arm prospective multi-centre trial; 6-month and 12-
month follow-up reported of projected 36-month follow-up (ongoing)
Lukban 2013b Not a randomised or quasi-randomised trial; a review paper
Miller 2007b Not a randomised or quasi-randomised trial; a review paper
Sand 2014b Not a randomised or quasi-randomised trial; a cost analysis of treatment
Sotomayor 2003 Not a randomised or quasi-randomised trial. Pilot clinical trial comparing 6-month and 12-month outcomes of
4 radiofrequency collagen denaturation treatment regimens, which differed in total numbers of radiofrequency
micro-remodeling sites and anatomical locations
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(Continued)
Takacs 2013 Not a randomised or quasi-randomised trial; a review paper
Vianello 2007 Not a randomised or quasi-randomised trial; a review paper
Wells 2007 Not a randomised or quasi-randomised trial; a single-arm multi-centre trial evaluating the feasibility, safety and
efficacy of oral sedation and a local anaesthetic regimen in performing radiofrequency collagen denaturation
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D A T A A N D A N A L Y S E S
Comparison 1. Transurethral radiofrequency collagen denaturation versus no treatment/sham treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Disease-specific quality of life:
number of women with an
I-QOL score improvement ≥
10 points at 12 months
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Clinician observations: objective
measurement of incontinence:
change in leak point pressure at
12 months
1 Mean Difference (IV, Random, 95% CI) Totals not selected
4 Other adverse event:
pain/dysuria: dysuria
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Other adverse event: (new)
detrusor overactivity: overactive
bladder symptoms
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Other adverse event: de novo
urinary retention: urinary
retention
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
7 Other adverse event: urinary
tract infection
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8 Other adverse event: haematuria 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
9 Other adverse event: hesitancy 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham
treatment, Outcome 1 Serious adverse events.
Review: Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence
Comparison: 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham treatment
Outcome: 1 Serious adverse events
Study or subgroup RF treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Appell 2006 0/110 0/63 Not estimable
0.01 0.1 1 10 100
Favours RF treatment Favours control
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Analysis 1.2. Comparison 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham
treatment, Outcome 2 Disease-specific quality of life: number of women with an I-QOL score improvement ≥
10 points at 12 months.
Review: Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence
Comparison: 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham treatment
Outcome: 2 Disease-specific quality of life: number of women with an I-QOL score improvement≥ 10 points at 12 months
Study or subgroup RF treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Appell 2006 43/89 23/53 1.11 [ 0.77, 1.62 ]
0.01 0.1 1 10 100
Favours control Favours RF treatment
Analysis 1.3. Comparison 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham
treatment, Outcome 3 Clinician observations: objective measurement of incontinence: change in leak point
pressure at 12 months.
Review: Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence
Comparison: 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham treatment
Outcome: 3 Clinician observations: objective measurement of incontinence: change in leak point pressure at 12 months
Study or subgroup RF treatment Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Appell 2006 87 -13.2 (39.2) 49 2 (33.8) -15.20 [ -27.75, -2.65 ]
-50 -25 0 25 50
Favours RF treatment Favours control
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Analysis 1.4. Comparison 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham
treatment, Outcome 4 Other adverse event: pain/dysuria: dysuria.
Review: Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence
Comparison: 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham treatment
Outcome: 4 Other adverse event: pain/dysuria: dysuria
Study or subgroup RF treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Appell 2006 10/110 1/63 5.73 [ 0.75, 43.70 ]
0.01 0.1 1 10 100
Favours RF treatment Favours control
Analysis 1.5. Comparison 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham
treatment, Outcome 5 Other adverse event: (new) detrusor overactivity: overactive bladder symptoms.
Review: Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence
Comparison: 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham treatment
Outcome: 5 Other adverse event: (new) detrusor overactivity: overactive bladder symptoms
Study or subgroup RF treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Appell 2006 19/110 8/63 1.36 [ 0.63, 2.93 ]
0.01 0.1 1 10 100
Favours RF treatment Favours control
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Analysis 1.6. Comparison 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham
treatment, Outcome 6 Other adverse event: de novo urinary retention: urinary retention.
Review: Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence
Comparison: 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham treatment
Outcome: 6 Other adverse event: de novo urinary retention: urinary retention
Study or subgroup RF treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Appell 2006 1/110 0/63 1.73 [ 0.07, 41.84 ]
0.01 0.1 1 10 100
Favours RF treatment Favours control
Analysis 1.7. Comparison 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham
treatment, Outcome 7 Other adverse event: urinary tract infection.
Review: Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence
Comparison: 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham treatment
Outcome: 7 Other adverse event: urinary tract infection
Study or subgroup RF treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Appell 2006 5/110 3/63 0.95 [ 0.24, 3.86 ]
0.01 0.1 1 10 100
Favours RF treatment Favours control
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Analysis 1.8. Comparison 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham
treatment, Outcome 8 Other adverse event: haematuria.
Review: Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence
Comparison: 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham treatment
Outcome: 8 Other adverse event: haematuria
Study or subgroup RF treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Appell 2006 1/110 0/63 1.73 [ 0.07, 41.84 ]
0.01 0.1 1 10 100
Favours RF treatment Favours control
Analysis 1.9. Comparison 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham
treatment, Outcome 9 Other adverse event: hesitancy.
Review: Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence
Comparison: 1 Transurethral radiofrequency collagen denaturation versus no treatment/sham treatment
Outcome: 9 Other adverse event: hesitancy
Study or subgroup RF treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Appell 2006 0/110 1/63 0.19 [ 0.01, 4.65 ]
0.002 0.1 1 10 500
Favours RF treatment Favours control
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A P P E N D I C E S
Appendix 1. Search strategy - Cochrane Incontinence Group Specialised Register
This review drew on the search strategy developed for the Cochrane Incontinence Group. We identified relevant trials from the
Cochrane Incontinence Group Specialised Trials Register. For more details of the search methods used to build the Specialised Register,
please see the Group’s module in The Cochrane Library. The Register contains trials identified from the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE and MEDLINE in process, ClinicalTrials.gov and WHO ICTRP and by handsearching
of journals and conference proceedings. Most of the trials in the Cochrane Incontinence Group Specialised Register are also contained
in CENTRAL. The date of the last search was 19 December 2014.
The terms used to search the Incontinence Group Specialised Register are given below.
(({DESIGN.CCT*} OR {DESIGN.RCT*}) AND ({INTVENT.SURG.RadioFreq*} OR
{INTVENT.SURG.transurethralMicrowave*}) AND {TOPIC.URINE.INCON*})
(All searches were of the keyword field of Reference Manager 2012.)
Appendix 2. Search strategy - EMBASE via Ovid SP
On 19 December 2014, EMBASE and EMBASE Classic were searched (1947 to 2014 Week 50) using the following strategy.
1. randomized controlled trial/
2. controlled study/
3. clinical study/
4. major clinical study/
5. prospective study/
6. meta analysis/
7. exp clinical trial/
8. randomization/
9. crossover procedure/ or double blind procedure/ or parallel design/ or single blind procedure/
10. placebo/
11. latin square design/
12. exp comparative study/
13. follow up/
14. pilot study/
15. family study/ or feasibility study/ or pilot study/ or study/
16. placebo$.tw.
17. random$.tw.
18. (clin$ adj25 trial$).tw.
19. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.
20. factorial.tw.
21. crossover.tw.
22. latin square.tw.
23. (balance$ adj2 block$).tw.
24. factorial design/
25. parallel design/
26. triple blind procedure/
27. community trial/
28. intervention study/
29. experimental study/
30. prevention study/
31. quasi experimental study/
32. or/1-31
33. (nonhuman not human).sh.
34. 32 not 33
35. incontinence/ or mixed incontinence/ or stress incontinence/ or urge incontinence/ or urine incontinence/
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36. continence/
37. overactive bladder/
38. micturition disorder/ or lower urinary tract symptom/ or pollakisuria/
39. urinary dysfunction/ or bladder instability/ or detrusor dyssynergia/ or neurogenic bladder/ or urinary urgency/ or urine extrava-
sation/
40. (incontinen$ or continen$).tw.
41. ((bladder or detrusor or vesic$) adj5 (instab$ or stab$ or unstab* or irritab$ or hyperreflexi$ or dys?ynerg$ or dyskinesi$ or
irritat$)).tw.
42. (urin$ adj2 leak$).tw.
43. ((bladder or detrusor or vesic$) adj2 (hyper$ or overactiv$)).tw.
44. (bladder$ adj2 (neuropath$ or neurogen* or neurolog$)).tw.
45. (nervous adj pollakisur$).tw.
46. 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45
47. catheter ablation/
48. radiofrequency ablation/
49. radiofrequency/
50. pulsed radiofrequency treatment/
51. radiofrequency radiation/
52. (radiofrequenc$ adj4 remodel$).tw.
53. (radiofrequenc$ adj4 denatur$).tw.
54. (transurethral adj2 radiofrequenc$).tw.
55. (rf adj4 remodel$).tw.
56. renessa.tw.
57. lyrette.tw
58. 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57
59. 34 and 46 and 58
Appendix 3. Search strategy - Google Scholar
(lyrette OR renessa OR transurethral collagen denaturation OR radiofrequency collagen denaturation OR radiofrequency collagen
remodeling OR transurethral collagen remodeling) AND stress urinary incontinence
The date of the last search was 19 December 2014.
Appendix 4. Search strategy - FDA website
renessa OR radiofrequency transurethral OR lyrette
The date of the last search was 19 December 2014.
Appendix 5. Search strategy - Current Controlled Trials
stress urinary incontinence
The date of the last search was 19 December 2014.
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Appendix 6. Search strategy - ClinicalTrials.gov
1. SUI AND (transurethral OR collagen OR denaturation OR remodeling)
2. stress urinary incontinence AND (transurethral OR collagen OR denaturation OR remodeling)
3. lyrette OR renessa
The date of the last search was 19 December 2014.
Appendix 7. Search strategy - WHO ICTRP
(SUI OR stress urinary incontinence) AND transurethral
The date of the last search was 19 December 2014.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This review is based on a published protocol (Dahm 2012), with differences as described here.
The focus of the review was broadened from ’stress urinary incontinence’ to ’urinary incontinence’ in accordance with editorial and
peer referee feedback.
In the Methods section ’Types of studies’, we clarified that we included parallel-group trials and excluded cluster-randomised and cross-
over trials for consistency with the ’Unit of analysis issues’ section of the protocol.
In theMethods section ’Types of outcomemeasures’, we clarified thatmeasurement of outcomes assessed in this reviewwas not a criterion
for inclusion. We rephrased the primary outcome ’Participant-reported measures: number of women reporting urinary incontinence
symptoms after transurethral collagen denaturation at time points defined by investigators’ to be applicable to all interventions assessed in
the review; now phrased as ’Participant-reported measures: number of women reporting UI symptoms after intervention at time points
defined by investigators’. In accordance with current recommendations that primary outcomes include at least one potential benefit and
at least one potential harm (O’Connor 2011), we added two primary outcomes that had been classified among the secondary outcomes
in the protocol; these are ’Disease-specific quality of life: disease-specific quality of life assessed through validated measures’ and ’Serious
adverse events: major vascular or visceral injury, bladder/urethral perforation, nerve damage, fistula formation or other major surgical
complications’. To accommodate these changes to the primary outcomes, we made the following changes to the secondary outcomes
of the review: removed the patient observations outcome ’Number of women with SUI not improved symptomatically as reported by
patient questionnaire, e.g. Incontinence Quality of Life (I-QOL) questionnaire, or other patient observations as reported by individual
trials’; changed the ’Quality of life’ outcome heading to ’Other quality of life’; removed the quality of life outcome ’Condition-specific
healthmeasures (specific instruments designed to assess incontinence)’; changed the ’Adverse events’ outcome heading to ’Other adverse
events’; removed the adverse events outcomes ’Major vascular or visceral injury’, ’Bladder or urethral perforation’, ’Nerve damage’,
’Other perioperative surgical complications’, ’De novo urge symptoms or urge incontinence’ and ’Erosion or fistula to vagina’; changed
the adverse events outcome ’Other serious adverse events reported by individual trials’ to ’Other adverse events reported by individual
trials’.We also removed the quantification of symptoms secondary outcome ’Incontinence episodes’ due to overlap with other outcomes.
In response to editorial and peer referee feedback, we changed the classification of the ’Repeat continence surgery’ outcome from the
’Other adverse events’ outcome heading to instead represent a separate outcome heading and outcome, ’Repeat continence surgery:
number of women undergoing repeat continence surgery’. Additionally, we added the subheading ’Main outcomes for ’Summary of
findings table” and listed there the outcomes included in the ’Summary of findings’ table, as the main outcomes were not specified in
the protocol.
In the Methods section ’Data extraction and management’, we clarified that data abstraction was performed independently by two
review authors. We also added the following statement to clarify the specific data extracted: “Extracted data included study design;
dates when the study was conducted; setting; participant inclusion and exclusion criteria; participant age; sample size of the study and
of each intervention group; details of interventions; details of outcomes relevant to the review including how measured, time points at
which they were measured and outcomes data; details of funding sources; declarations of interest among primary study authors; and
study details relevant to risk of bias assessment.”
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In the Methods section ’Assessment of risk of bias in included studies’, we updated the risk of bias judgements to ’low’, ’unclear’ or
’high’ risk of bias and updated the risk of bias domain names for consistency with the current version of tool for assessing risk of bias
of The Cochrane Collaboration (Higgins 2011a). We also clarified that each risk of bias for blinding of participants and personnel,
blinding of outcome assessment and incomplete outcome data was assessed on an outcome-specific basis.
We expanded the Methods section ’Measures of treatment effect’ to clarify the data that we sought and used to calculate the stated
measures of treatment effect.
In the Methods section ’Unit of analysis issues’, we clarified that no studies with multiple intervention groups were identified although
they were eligible for inclusion.
In the protocol we had planned to analyse all data by intention-to-treat analysis, imputing missing data with replacement values.
However, in the review we based analyses on available data only and addressed missing data in the risk of bias assessment in accordance
with guidance provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011c). We revised the Methods
section ’Dealing with missing data’ to reflect this change.
As only one study was included in the review, it was neither necessary to assess heterogeneity nor to test for funnel plot asymmetry to
assess potential publication bias, as we had planned in the protocol.
We attempted to obtain study protocols to assess for reporting bias in accordance with Cochrane standards, and we added a statement
to the Methods section ’Assessment of reporting biases’ to reflect this.
In the protocol, we planned to pool data from eligible studies in a meta-analysis, but this was not possible as only one study was included
in the review. We also clarified the meta-analysis methods that we planned to use in the review as the Mantel-Haenszel method for
dichotomous data and the inverse variance method for continuous data, as these methods were not specified in the protocol. We revised
the Methods section ’Data synthesis’ to reflect these changes.
We were unable to perform the predefined subgroup analyses because identified data were limited, and we reported a post hoc subgroup
analysis by degree of baselineUI as performed in the included trial.We updated theMethods section ’Subgroup analysis and investigation
of heterogeneity’ accordingly.
We were unable to perform a predefined sensitivity analysis according to methodological quality, given the paucity of data. We indicated
this in the Methods section ’Sensitivity analysis’.
We moved the description of methods used to rate the quality of evidence and to prepare a ’Summary of findings’ table from the
Methods section ’Assessment of risk of bias in included studies’ to the Methods section ”Summary of findings’ table’.
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